84
43
Growth Score
-5 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
382240
OrganoTherapeutics use mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease.
- Silvia Bolognin: Co-FounderPast Role: Braingineering Technologies, Co-Founder / CTO
- Jens Schwamborn: CEOPast Role: Braingineering Technologies, CSO
About the Company
OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease. We screen new molecules on our proprietary human-specific minibrains which represent a model mimicking faithfully the human Parkinson’s disease pathology. OrganoTherapeutics aims at developing
new drug candidates against Parkinson’s disease which are tested in state-of-the art 3D patient models. OrganoTherapeutics has developed first own proprietary drug candidates and has access to attractive libraries for further screening.
